BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2014

Dec 23, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2014-12-19

Reporting Person: Sheridan William P (Senior VP - CMO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-12-19	Emp. Stock Option (Right to Buy)	$5.45	A	17000	Acquired	2023-08-08	Common Stock (17000)	Direct

Footnotes

F1: On December 19, 2014, the U.S. Food and Drug Administration (FDA) approved RAPIVAB (peramivir injection), an intravenous (i.v.) neuraminidase inhibitor for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in August 2013 has been met. Therefore, 25% of the performance-based stock options vested on December 19, 2014.